Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) wins prestigious 2022 prix galien usa best biotechnology product award

Inmazeb is the first fda-approved treatment for zaire ebolavirus tarrytown, n.y. , oct. 28, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) has been recognized as the "best biotechnology product" of 2022 by the galien foundation, which acknowledges extraordinary scientific innovations that improve the human condition.
REGN Ratings Summary
REGN Quant Ranking